TD Cowen Maintains Buy on Guardant Health, Raises Price Target to $42
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Dan Brennan maintains a Buy rating on Guardant Health (NASDAQ:GH) and raises the price target from $41 to $42.
August 08, 2024 | 6:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TD Cowen analyst Dan Brennan maintains a Buy rating on Guardant Health and raises the price target from $41 to $42.
The Buy rating and increased price target from a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100